Genomic Data
Solutions for Pharma

Empowering Pharma R&D with Rare Disease Genomic Intelligence

Comprehensive genomic data de-risks drug programs

Genomenon combines AI and human expertise to deliver a comprehensive view of the genetics of your disease of interest, from discovery to commercialization

Understand Disease Mechanisms

Uncover pathogenic variants and relevant biomarkers to reveal genetic drivers of disease

Survey the Patient Universe

Review all published patient data annotated with demographics, genotype, phenotypes, and CDx information

Validate Disease Prevalence

Estimate market potential with precise genetic evidence and up-to-date population databases

Increase Diagnostic Yield

Drive disease, trial and treatment awareness through our global network of clinical diagnostic labs

In precision medicine, typical methods of gathering data often fall short. In fact open-access resources miss empirical evidence for 70% of clinically significant variants. If you rely on data from incomplete genomic resources, you are missing critical genomic data that can impact your entire drug program.

Are you making multimillion-dollar decisions based
on incomplete genomic data?

Empirical evidence for

70% of Clinically Significant Variants

Is missed in routine searches using traditional resources, such as ClinVar, PubMed, and GoogleScholar.

Incomplete genomic data puts drug programs at risk

The Wrong Variants

The Wrong Variants

Gaps in knowledge of disease mechanisms and enrolling patients with the wrong genomic biomarkers can dilute trial results

Inaccurate Market Analysis

Inaccurate Market Analysis

Missing pathogenic variants may result in underestimating prevalence, which could impair investment, trial design, and pricing

Insufficient Diagnostic Data

Insufficient Diagnostic Data

Open-access databases lack sufficient evidence, reducing diagnostic yield from genomic testing methods, labs, and the scientific literature

Get a comprehensive picture of your disease of interest

Genomenon’s Genomic Intelligence in Action

Expanding Clinical Trial Inclusion Data
Learn about how our unique AI-powered curation process delivers new insights into pathogenic variants in patients – and how these information can be used to increase trial enrollment
(3:42 read)

Accurately Estimating Rare Disease Prevalence
Inozyme Pharma partnered with Genomenon to get a more accurate estimate of ENPP1 Deficiency prevalence. Our findings revealed it is more than 3x more prevalent thant previously found (14:00 read)

Navigating Global Regulatory Approvals
Loxo@Lilly partnered with Genomenon to identify and confirm activating RET gene variants associated with rare cancers for submission to the Japanese regulatory Authority PMDA (56:00 watch)